Add like
Add dislike
Add to saved papers

A Prospective Longitudinal Study of Trajectories of Depressive Symptoms after Dysvascular Amputation.

OBJECTIVE: Characterize the course of depressive symptoms during the first year after dysvascular amputation and identify factors that predict symptom trajectories.

DESIGN: Prospective cohort study of individuals undergoing lower extremity amputation (LEA), surveyed at 4 timepoints (peri-operative period, 6 weeks, 4 months, and 12 months post-amputation). Multilevel modeling was used to describe and predict trajectories.

SETTING: Four Veterans Affairs medical centers, a university hospital, and a level I trauma center.

PARTICIPANTS: Participants (N = 141; 74% retention) were a consecutive sample, eligible if they were undergoing their first unilateral LEA secondary to dysvascular disease.

INTERVENTIONS: Not applicable MAIN OUTCOME MEASURE: Patient Health Questionnaire-9 RESULTS: Approximately 40% of participants endorsed at least moderate depressive symptoms at perioperative baseline. Individuals with greater depressive symptoms in the perioperative period concurrently reported greater pain, poorer self-rated health, and prior mental health treatment. In the first 6 weeks after amputation there was a substantial improvement in depressive symptoms, especially among individuals with greater symptoms at baseline. Depressive symptoms were generally stable after 6 weeks. None of the covariates assessed significantly predicted trajectories of depressive symptom improvement.

CONCLUSIONS: Watchful waiting may be the most appropriate course of action for many patients in the first six weeks after amputation. After six weeks, however, symptom levels tend to stabilize, suggesting that active intervention is called for if patients remain depressed at this point. Some patients may benefit from more proactive intervention, such as those with prior mental health treatment histories.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app